Assembly Biosciences Debt to Equity Ratio 2010-2023 | ASMB
Current and historical debt to equity ratio values for Assembly Biosciences (ASMB) over the last 10 years. The debt/equity ratio can be defined as a measure of a company's financial leverage calculated by dividing its long-term debt by stockholders' equity. Assembly Biosciences debt/equity for the three months ending September 30, 2023 was 0.00.
| Assembly Biosciences Debt/Equity Ratio Historical Data |
| Date |
Long Term Debt |
Shareholder's Equity |
Debt to Equity Ratio |
| 2023-09-30 |
$0.01B |
$0.04B |
0.24 |
| 2023-06-30 |
$0.01B |
$0.06B |
0.21 |
| 2023-03-31 |
$0.01B |
$0.07B |
0.18 |
| 2022-12-31 |
$0.02B |
$0.08B |
0.23 |
| 2022-09-30 |
$0.02B |
$0.10B |
0.19 |
| 2022-06-30 |
$0.02B |
$0.12B |
0.16 |
| 2022-03-31 |
$0.02B |
$0.15B |
0.11 |
| 2021-12-31 |
$0.02B |
$0.17B |
0.13 |
| 2021-09-30 |
$0.02B |
$0.23B |
0.11 |
| 2021-06-30 |
$0.03B |
$0.23B |
0.13 |
| 2021-03-31 |
$0.03B |
$0.25B |
0.13 |
| 2020-12-31 |
$0.04B |
$0.24B |
0.18 |
| 2020-09-30 |
$0.04B |
$0.27B |
0.13 |
| 2020-06-30 |
$0.03B |
$0.27B |
0.10 |
| 2020-03-31 |
$0.06B |
$0.25B |
0.24 |
| 2019-12-31 |
$0.07B |
$0.27B |
0.24 |
| 2019-09-30 |
$0.07B |
$0.16B |
0.43 |
| 2019-06-30 |
$0.07B |
$0.18B |
0.38 |
| 2019-03-31 |
$0.07B |
$0.19B |
0.36 |
| 2018-12-31 |
$0.06B |
$0.21B |
0.27 |
| 2018-09-30 |
$0.05B |
$0.23B |
0.23 |
| 2018-06-30 |
$0.05B |
$0.09B |
0.60 |
| 2018-03-31 |
$0.05B |
$0.10B |
0.52 |
| 2017-12-31 |
$0.06B |
$0.11B |
0.50 |
| 2017-09-30 |
$0.07B |
$0.05B |
1.38 |
| 2017-06-30 |
$0.07B |
$0.06B |
1.17 |
| 2017-03-31 |
$0.07B |
$0.07B |
0.98 |
| 2016-12-31 |
$0.02B |
$0.08B |
0.23 |
| 2016-09-30 |
$0.02B |
$0.09B |
0.21 |
| 2016-06-30 |
$0.02B |
$0.10B |
0.17 |
| 2016-03-31 |
$0.02B |
$0.11B |
0.14 |
| 2015-12-31 |
$0.02B |
$0.12B |
0.13 |
| 2015-09-30 |
$0.01B |
$0.13B |
0.11 |
| 2015-06-30 |
$0.01B |
$0.13B |
0.11 |
| 2015-03-31 |
$0.01B |
$0.13B |
0.11 |
| 2014-12-31 |
$0.01B |
$0.06B |
0.22 |
| 2014-09-30 |
$0.01B |
$0.05B |
0.28 |
| 2014-06-30 |
$0.00B |
$0.02B |
0.07 |
| 2014-03-31 |
$0.00B |
$0.02B |
0.07 |
| 2013-12-31 |
$0.00B |
$0.02B |
0.11 |
| 2013-09-30 |
$0.00B |
$0.03B |
0.08 |
| 2013-06-30 |
$0.00B |
$0.03B |
0.08 |
| 2013-03-31 |
$0.00B |
$0.04B |
0.06 |
| 2012-12-31 |
$0.00B |
$0.02B |
0.15 |
| 2012-09-30 |
$0.00B |
$0.02B |
0.13 |
| 2012-06-30 |
$0.00B |
$0.03B |
0.13 |
| 2012-03-31 |
$0.00B |
$0.03B |
0.14 |
| 2011-12-31 |
$0.00B |
$0.04B |
0.07 |
| 2011-09-30 |
$0.00B |
$0.05B |
0.02 |
| 2011-06-30 |
$0.00B |
$0.01B |
0.22 |
| 2011-03-31 |
$0.00B |
$0.01B |
0.13 |
| 2010-12-31 |
$0.00B |
$0.01B |
0.26 |
| 2010-09-30 |
$0.00B |
$0.00B |
0.00 |
| 2010-06-30 |
$0.00B |
$0.00B |
0.00 |
| 2010-03-31 |
$0.00B |
$0.00B |
0.00 |
| 2009-12-31 |
$0.01B |
$-0.01B |
-1.01 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Generic Drugs |
$0.071B |
$0.007B |
|
Assembly Biosciences, Inc. is a biopharmaceutical company. It develops therapies for infectious diseases and other disorders of the gastrointestinal (GI) system. Assembly's product portfolio consists of two late stage assets: VEN 307 for relief from pain associated with anal fissures and VEN 308 for the treatment of fecal incontinence. The Company is also developing novel microbiome-based technology for targeted oral delivery of therapeutic bacteria, complex proteins, viral antigens and small molecules to treat intractable infectious diseases of the GI tract, such as C. difficile infections. Assembly Biosciences Inc., formerly known as Ventrus Biosciences, Inc., is based in New York.
|
